Business Wire

Winners Announced in Prestigious GCCA Photo Competition Which Highlights Beauty and Essential Role of Concrete Throughout World

15.2.2023 15:30:00 EET | Business Wire | Press release

Share

A stunning image of a skateboard park in the United Arab Emirates has been named Concrete in Life Photo of the Year. It wins a top prize of $10,000 (ten thousand US dollars) in a global competition, which highlights the essential role that concrete plays around the world.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230215005136/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Ferdz Bedana, winner Urban Concrete Professional and overall winner, Concrete in Life Photo of Year. Location Sharjah, UAE

The photo, taken by professional photographer, Ferdz Bedana, in Sharjah, was announced as the overall winner in a live Instagram broadcast, on 15th February. It was selected from more than 14,000 photos submitted by both amateur and professional photographers from every continent, in the annual competition run by the Global Cement and Concrete Association.

Thomas Guillot, GCCA Chief Executive said: “Concrete is the second most used substance on earth after water and plays a vital part in modern infrastructure and society. Through the work of the GCCA and our members, to implement our 2050 Net Zero Roadmap, we are working hard and making progress in reducing its environmental impact. These amazing photos capture the appeal of concrete design and the essential role it plays in modern life and communities everywhere.”

Entrants from around the world submitted photos across four categories: concrete infrastructure, concrete beauty and design, urban concrete, and concrete in daily life, with each section divided between professional photographers and amateurs, often with smart phones. The breadth and variety of all the entries highlight the way concrete supports life around the world, from the giant to the small form, as well as the material’s grace, beauty and crucial supporting role.

Eight category winners each receive a prize of $2,500 (two thousand, five hundred US dollars) each. As well as Ferdz Bedana’s skateboarder image, the category winners include images of a waterfall and a roller-skater race, both taken in Indonesia, a stunning city interchange in China, rice mills in Bangladesh, a university building in Mexico, a metro station in Dubai and a Mosque in Istanbul, Turkey.

Ferdz Bedana who took the overall Concrete in Life Photo of Year in Sharjah, said: “It’s a great honour to be the overall winner of the Concrete in Life 2022 competition and spread the story of how concrete is a big contribution in our life. I was interested to take a photo of this skatepark when I saw a boy enjoying playing in a substantially artistic concrete design.”

Chris George, Content Director at Digital Camera World, and one of the competition judges said about the winning photo: “This was an amazing capture, that perfectly shows the energy of skateboarding against the organic form of the manmade structure.”

Fellow judge, freelance writer and photographer Norman Miller added: “It’s a real skill to capture fast moving subject while showing mastery of framing and control of lighting.”

Thomas Guillot, GCCA Chief Executive added: “Congratulations to Ferdz Bedana and all our category winners. Check out our website to see all the shortlisted entries who were all outstanding.”

The GCCA and its member companies, which account for 80% of global cement production capacity outside of China, as well as key Chinese manufacturers, are committed to reducing and eliminating CO2 emissions through implementation of the Concrete Future - 2050 Net Zero Roadmap – the first heavy industry to set out such a detailed plan.

Notes to editors:

Images available for media to use here .

Video of Instagram broadcast announcing winners available here .

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further details, or interview requests:
Simon Thomson, Head of Media, GCCA
simon.thomson@gccassociation.org / +44 7380 972282

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye